Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
- New and updated data from across our?broad cancer portfolio including phase III results in breast, lung and prostate cancers
- New integrated analyses from our tumour agnostic Rozlytrek??(entrectinib) clinical development programme
- Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating GavretoTM?(pralsetinib) for the treatment of people with RET-mutant medullary thyroid cancer
- Impact of COVID-19 on cancer care: Roche live virtual panel discussions and Q&As featuring world leading healthcare experts
Medicine | Abstract title | Abstract number |
Triple-negative breast cancer | ||
Tecentriq??(atezolizumab) | Primary results from IMpassion131, a double-blind placebo-controlled randomised phase 3 trial of first-line paclitaxel (PAC) +/- atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC) | LBA15 (Oral), Saturday, 19 September, (Channel 1) 16:20-16:32 CEST |
Tecentriq | IMpassion031: results from a Ph 3 study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC) | LBA11 (Oral), Sunday, 20 September, (Channel 3) 12:30-12:42 CEST |
Tecentriq | IMpassion130: final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer | LBA16 (Oral), Saturday, 19 September, (Channel 1) 16:32-16:44 CEST |
HER2-positive breast cancer | ||
Phesgo? (pertuzumab- trastuzumab) | Patient preference for the pertuzumab?trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study | Presentation #165MO (Oral), Friday, 18 September (On-demand) |
Perjeta??(pertuzumab) and Herceptin??(trastuzumab) | Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator?s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) | Presentation #228P (Poster), Thursday, 17 September (On-demand) |
HR-positive breast cancer | ||
GDC-0077 | Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2? LA/MBC) | Presentation #355TiP (Poster), Thursday, 17 September (On-demand) |
GDC-0077 | PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2? BC) | Presentation #336P (Poster), Thursday, 17 September (On-demand) |
Ipatasertib | Ipatasertib (IPAT) + paclitaxel (PAC) for?PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase 3 trial | Presentation #283MO (Oral), Friday, 18 September (On-demand) |
Lung cancer | ||
Alecensa??(alectinib) | Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from Blood First Assay Screening Trial (BFAST) and comparison with real-world data (RWD) | Presentation #1307P (Poster), Thursday, 17 September (On-demand) |
Alecensa | Blood First Assay Screening Trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses | Presentation #1301P (Poster), Thursday, 17 September (On-demand) |
Tecentriq | IMpower133: characterisation of long-term survivors treated first-line with chemotherapy ? atezolizumab in extensive-stage small cell lung cancer | Presentation #1781MO (Mini-oral), Friday, 18 September (On-demand) |
Tecentriq | 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC | Presentation #1271P (Poster), Thursday, 17 September (On-demand) |
Tecentriq | IMscin001: phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) | Presentation #1270P (Poster), Thursday, 17 September (On-demand) |
Flatiron Health data in lung cancer | ||
Real world data | Patterns of care and outcomes in carcinoma of unknown primary: A SEER-Medicare study | Presentation #519P (Poster), Thursday, 17 September (On-demand) |
Real world data | Pan-cancer analysis of homologous recombination (HR)-associated alterations (alts) and genome-wide loss of heterozygosity (gLOH) | Presentation #85MO (Oral), Friday, 18 September (On-demand) |
Solid tumours | ||
Rozlytrek??(entrectinib) | Efficacy and safety of entrectinib in locally advanced /metastatic ROS1 fusion-positive NSCLC: an updated integrated analysis | Presentation #1287P (Poster), Thursday, 17 September (On-demand) |
Rozlytrek | Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline | Presentation #1288P (Poster), Thursday, 17 September (On-demand) |
Rozlytrek | Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases | Presentation #364O (Oral), Sunday, 20 September, 13:38-13:50 CEST |
GavretoTM?(pralsetinib) | Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+MTC) (Blueprint) | Presentation #1913O (Oral) Sunday, 20 September, 15:21-15:33 CEST |
Genitourinary cancers | ||
Tecentriq | Patient-reported outcomes (PROs) from IMvigor130: a global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) | Presentation #698O (Oral), Saturday, 19 September, 17:16-17:28 CEST |
Perjeta and Herceptin | End-of-study analysis from JACOB: a phase III study of pertuzumab (P) + trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC) | Presentation #1423MO (Oral), Friday, 18 September (On-demand) |
Ipatasertib | IPATential150: phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC) | LBA4 (Presidential symposium II), Sunday, 20 September, (Channel 1) 19:02-19:14 CEST |
Liver cancer | ||
Tecentriq and Avastin??(bevacizumab) | Efficacy of atezolizumab + bevacizumab After Disease Progression With Atezo Monotherapy in Patients With Previously Untreated, Unresectable Hepatocellular Carcinoma (HCC) | Presentation #986P (Poster), Thursday, 17 September (On-demand) |
Tecentriq and Avastin | IMbrave150: management of adverse events of special interest (AESIs) for atezolizumab and bevacizumab in unresectable HCC | Presentation #1008P (Poster), Thursday, 17 September (On-demand) |
Gynecological cancer | ||
Tecentriq | Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase 3 trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC) | LBA31 (Oral) Monday, 21 September, (Channel 3) 16:20-16:32 CEST |